Hydrogen-bond formation of the residue in H-loop of the nucleotide binding domain 2 with the ATP in this site and/or other residues of multidrug resistance protein MRP1 plays a crucial role during ATP-dependent solute transport  by Yang, Runying & Chang, Xiu-bao
1768 (2007) 324–335
www.elsevier.com/locate/bbamemBiochimica et Biophysica ActaHydrogen-bond formation of the residue in H-loop of the nucleotide binding
domain 2 with the ATP in this site and/or other residues of multidrug
resistance protein MRP1 plays a crucial role during
ATP-dependent solute transport
Runying Yang, Xiu-bao Chang ⁎
Mayo Clinic College of Medicine, Mayo Clinic Arizona, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA
Received 21 June 2006; received in revised form 12 October 2006; accepted 14 November 2006
Available online 18 November 2006Abstract
MRP1 couples ATP binding/hydrolysis to solute transport. We have shown that ATP binding to nucleotide-binding-domain 1 (NBD1) plays a
regulatory role whereas ATP hydrolysis at NBD2 plays a crucial role in ATP-dependent solute transport. However, how ATP is hydrolyzed at
NBD2 is not well elucidated. To partially address this question, we have mutated the histidine residue in H-loop of MRP1 to either a residue that
prevents the formation of hydrogen-bonds with ATP and other residues in MRP1 or a residue that may potentially form these hydrogen-bonds.
Interestingly, substitution of H827 in NBD1 with residues that prevented formation of these hydrogen-bonds had no effect on the ATP-dependent
solute transport whereas corresponding mutations in NBD2 almost abolished the ATP-dependent solute transport completely. In contrast,
substitutions of H1486 in H-loop of NBD2 with residues that might potentially form these hydrogen-bonds exerted either full function or partial
function, implying that hydrogen-bond formation between the residue at 1486 and the γ-phosphate of the bound ATP and/or other residues, such
as putative catalytic base E1455, together with S769, G771, T1329 and K1333, etc., holds all the components necessary for ATP binding/
hydrolysis firmly so that the activated water molecule can efficiently hydrolyze the bound ATP at NBD2.
© 2006 Elsevier B.V. All rights reserved.Keywords: MRP1; Nucleotide binding domain (NBD); ATP binding/hydrolysis; Hydrogen-bond; ATP-dependent solute transport1. Introduction
Cells over-expressing P-glycoprotein (P-gp or ABCB1)
[1,2], breast cancer resistance protein (BCRP or ABCG2) [3,4]
and/or multidrug resistance protein (MRP1 or ABCC1) [5,6]
are resistant to a broad range of anticancer drugs. P-gp is a
170 kDa membrane-bound glycoprotein with two transmem-
brane domains (TMD) and two nucleotide binding domainsAbbreviations: BHK, baby hamster kidney; Sf21, Spodoptera frugiperda 21;
ABC, ATP binding cassette; MRP1, multidrug resistance protein; P-gp, P-
glycoprotein; NBD, nucleotide binding domain; LTC4, leukotriene C4;
8-N3ATP, 8-azidoadenosine 5′-triphosphate; EGTA, ethylene glycol-bis(β-
aminoethyl ether)N,N,N,N-tetraacetic acid; SDS, sodium dodecyl sulfate; X-gal,
5-bromo-4-chloro-indolyl-β-D-galactoside and IPTG, isopropylthio-β-D-
galactoside
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doi:10.1016/j.bbamem.2006.11.009(NBD) [2,7,8]. MRP1 is a 190 kDa membrane-bound gly-
coprotein with a core structure of P-gp and an extra N-terminal
domain composed of TMD0 and L0 linker region [6,9,10].
BCRP is a 72 kDa membrane-bound protein with an NBD
followed by a TMD with six transmembrane segments
[3,4,11,12]. Although the topology of BCRP is somewhat
different from P-gp or MRP1 as it has only half of the core
structure of P-gp [3,4,11,12], the functional unit of BCRP is a
homodimer with two TMDs and two NBDs [13–18]. Thus,
although their molecular weights, amino acid compositions and
topologies are different, these ATP-binding cassette (ABC)
transporters share a common architecture composed of two
NBDs and two TMDs, which are believed to be used to couple
ATP binding/hydrolysis to anticancer drug transport.
Sequence dissimilarities between NBD1 and NBD2 of
MRP1 protein imply that they may play different roles during
ATP-dependent solute transport. Indeed, substitution of the
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NBD2 with a non-charged amino acid abolished the ATP-
dependent solute transport activity completely, whereas the
corresponding substitution in NBD1 decreased the transport
activity to approximately half of wild-type MRP1 [19,20]. In
addition, it has been found that NBD1 has a higher affinity for
ATP than that of NBD2 [21]. Thus, ATP binding to NBD1 and
NBD2 of MRP1 protein should be a sequential event. Once ATP
is bound to NBD1, it induces conformational changes of the
protein and enhances ATP binding to NBD2 [22]. If mutation in
NBD1 significantly impairs ATP binding at the mutated NBD1,
it also severely affects the ATP binding at the un-mutated NBD2
[23], implying that ATP binding at NBD1 plays an important
role during the NBD1·ATP·ATP·NBD2 heterodimer sandwich
formation [24]. However, ATP hydrolysis at the NBD1 seems
likely not essential since substitution of the putative catalytic
base D793 in NBD1 with a non-acidic amino acid does not
significantly affect the ATP-dependent solute transport [25,26].
Conversely, substitution of the putative catalytic base E1455 in
NBD2 with a non-acidic amino acid almost abolished the ATP-
dependent solute transport activity completely [25,26], imply-
ing that ATP hydrolysis at the NBD2 of MRP1 is essential.
However, it is still not clear why some of the NBD2 mutations
significantly decreased the affinity for ATP at the mutated NBD2
and ATP-dependent solute transport activity, whereas other
NBD2 mutations significantly decreased the affinity for ATP,
but increased the ATP-dependent solute transport activity. For
example, replacement of the aromatic Y1302 residue, which
should interact with the adenine ring of the bound ATP, with a
polar cysteine residue that significantly decreased the affinity for
ATP at the mutated NBD2, but increased the ATP-dependent
solute transport activity [27]. In contrast, mutations of the residue
that should interact with the γ-phosphate of the bound ATP
[28,29], such as K1333L [20], significantly decreased the ATP
binding at the mutated NBD2 [23] and almost abolished the ATP-
dependent solute transport activity completely. Accordingly, mu-
tations of the residues that should interact with the γ-phosphate of
the boundATP [28,29], such asK1333M[19] orG771A [30], also
almost abolished the ATP-dependent solute transport activity
completely. Thus, we speculated that the hydrogen-bond forma-
tion between the residues involved in ATP binding and the γ-
phosphate of the bound ATP in NBD2 might play an important
role during the ATP hydrolysis. In this report we havemutated the
histidine residue in H-loop to either a residue that prevents the
formation of hydrogen-bonds with ATP and other residues in
MRP1 or a residue that may potentially form these hydrogen-
bonds and found that hydrogen-bond formation between the
histidine residue in H-loop of NBD2 and the γ-phosphate of the
bound ATP and/or other residues plays a crucial role during the
ATP hydrolysis at NBD2 and ATP-dependent solute transport.2. Materials and methods
2.1. Materials
Sodium orthovanadate, EGTA, isopropylthio-β-D-galactoside (IPTG),
5-bromo-4-chloro-indolyl-β-D-galactoside (X-gal) and ATP were purchasedfrom Sigma. [α-32P]-8-N3ATP and [γ-
32P]-8-N3ATP were purchased from
Affinity Labeling Technologies. ([14,15,19,20-3H)-leukotriene C4 (LTC4) was
from NEN Life Science Products. CellFECTIN reagent, DMEM/F12 medium
and Grace's insect cell culture medium were from Invitrogen. Fetal bovine
serum was from Gemini Bio-Products. Stratalinker UV Crosslinker 2400 model
(wavelength 254 nm) and QuikChange site-directed mutagenesis kit were from
Stratagene. Chemiluminescent substrates were from Pierce.2.2. Generation of constructs
N-half (1–932) and C-half (933–1531) of human MRP1 cloned into pDual
expression vector [26] was used as a template for the in vitro mutagenesis. The
histidine residue at position of 827 or 1486 was mutated to either leucine or
phenylalanine (Fig. 1A, H827L, H827F, H1486L or H1486F) by using the
forward/reverse primers and the QuikChange site-directed mutagenesis kit from
Stratagene [20]. The forward and reverse primers for thesemutations are: H827L/
forward, 5′-CGG ATC TTG GTC ACG CTC AGC ATG AGC TAC TTG-3′;
H827L/reverse, 5′-CAA GTA GCT CAT GCT GAG CGT GAC CAA GAT
CCG-3′; H1486L/forward, 5′-GTC CTCACCATCGCC CTC CGGCTCAAC
ACCATC-3′; H1486L/reverse, 5′-GAT GGT GTT GAG CCGGAGGGCGAT
GGT GAG GAC-3′; H827F/forward, 5′-CGG ATC TTG GTC ACG TTC AGC
ATG AGC TAC TTG-3′; H827F/reverse, 5′-CAA GTA GCT CAT GCT GAA
CGTGAC CAAGAT CCG-3′; H1486F/forward, 5′-GTC CTCACCATCGCC
TTC CGG CTC AAC ACC ATC-3′; H1486F/reverse, 5′-GAT GGT GTT GAG
CCG GAA GGC GAT GGT GAG GAC-3′. These mutations (Fig. 4A, H827L,
H827F, H1486L, H1486F, H827L/H1486L or H827F/H1486F) were also intro-
duced into full length MRP1 cDNA by using the QuikChange site-directed
mutagenesis kit [20] with the plasmid DNA pNUT/MRP1/His [31] as a template
and the forward/reverse oligonucleotides shown above as primers. In addition,
the following mutations as shown in Fig. 5A (H827D, H1486D, H827D/
H1486D, H827N, H1486N, H827N/H1486N, H827E, H1486E, H827E/
H1486E, H827Q, H1486Q, H827Q/H1486Q, H827Y, H1486Y, H827Y/
H1486Y, H827W, H1486W and H827W/H1486W) were also introduced into
the full length MRP1 cDNA by using the following primers: H827D/forward,
5′-CGG ATC TTG GTC ACG GAC AGC ATG AGC TAC TTG-3′; H827D/
reverse, 5′-CAA GTA GCT CAT GCT GTC CGT GAC CAA GAT CCG-3′;
H1486D/forward, 5′-GTC CTC ACC ATC GCC GAC CGG CTC AAC ACC
ATC-3′; H1486D/reverse, 5′-GAT GGT GTT GAG CCGGTC GGC GAT GGT
GAGGAC-3′; H827N/forward, 5′-CGGATC TTG GTCACGAACAGCATG
AGC TAC TTG-3′; H827N/reverse, 5′-CAA GTA GCT CAT GCT GTT CGT
GACCAAGATCCG-3′; H1486N/forward, 5′-GTCCTCACCATCGCCAAC
CGGCTCAACACCATC-3′; H1486N/reverse, 5′-GAT GGTGTTGAGCCG
GTT GGC GAT GGT GAG GAC-3′; H827E/forward, 5′-CGG ATC TTG GTC
ACG GAG AGC ATG AGC TAC TTG-3′; H827E/reverse, 5′-CAA GTA GCT
CAT GCT CTC CGT GAC CAAGAT CCG-3′; H1486E/forward, 5′-GTC CTC
ACC ATC GCC GAG CGG CTC AAC ACC ATC-3′; H1486E/reverse, 5′-GAT
GGTGTTGAGCCGCTCGGCGATGGTGAGGAC-3′; H827Q/forward, 5′-
CGG ATC TTG GTC ACG CAG AGC ATG AGC TAC TTG-3′; H827Q/
reverse, 5′-CAA GTA GCT CAT GCT CTG CGT GAC CAA GAT CCG-3′;
H1486Q/forward, 5′-GTC CTC ACC ATC GCC CAG CGG CTC AAC ACC
ATC-3′; H1486Q/reverse, 5′-GAT GGT GTT GAG CCG CTG GGC GAT GGT
GAG GAC-3′; H827Y/forward, 5′-CGG ATC TTG GTC ACG TAC AGC ATG
AGC TAC TTG-3′; H827Y/reverse, 5′-CAA GTA GCT CAT GCT GTA CGT
GACCAAGATCCG-3′; H1486Y/forward, 5′-GTC CTCACCATCGCCTAC
CGGCTCAACACCATC-3′; H1486Y/reverse, 5′-GAT GGTGTTGAGCCG
GTAGGCGATGGTGAGGAC-3′; H827W/forward, 5′-CGGATC TTGGTC
ACG TGG AGC ATG AGC TAC TTG-3′; H827W/reverse, 5′-CAA GTA GCT
CATGCTCCACGTGACCAAGATCCG-3′; H1486W/forward, 5′-GTCCTC
ACCATCGCCTGGCGGCTCAACACCATC-3′; H1486W/reverse, 5′-GAT
GGT GTT GAG CCG CCA GGC GAT GGT GAG GAC-3′. The underlined
sequences are codons for mutated residues. The regions containing these
mutations were sequenced to confirm that the correct clones were obtained.
2.3. Cell culture and cell lines expressing MRP1
Baby hamster kidney (BHK-21) cells were cultured in DMEM/F12
medium supplemented with 5% fetal bovine serum at 37 °C in 5% CO2.
Table 1
Mean Kd (8-N3ATP) values of wild-type and mutant MRP1
Samples Kd
a of NBD1
(μM 8-N3ATP)
Kd of NBD2
(μM 8-N3ATP)N-half C-half
Wild-type Wild-type 11.7±2.7 32.4±2.5
H827L Wild-type 59.5±0.5 b 60.0±3.0
Wild-type H1486L 31.0±0.8 58.7±1.3
H827L H1486L 59.7±1.3 53.0±0.8
H827F Wild-type 12.3±0.5 32.7±0.9
Wild-type H1486F 11.5±0.5 33.0±1.0
H827F H1486F 58.0±1.0 51.5±0.5
a The Kd (8-N3ATP) values (n=3) of wild-type and mutant MRP1s were
derived from Fig. 2. The amount of [α-32P]-8-N3ATP incorporated into the
N-half (NBD1) or C-half (NBD2) fragment was measured by Packard Instant
Imager and plotted out against [α-32P]-8-N3ATP concentration. Kd is calculated
by using the formula: Kd= (Lmax−L)[S] /L, where [S] is the concentration of
[α-32P]-8-N3ATP, L is the amount of [α-
32P]-8-N3ATP labeled on NBD1 or
NBD2 and Lmax is the maximum amount of [α-
32P]-8-N3ATP labeled on NBD1
or NBD2.
b Statistical analysis indicated that the Kd values of NBD1 from H827L,
H1486L, H827L/H1486L and H827F/H1486F or the Kd values of NBD2 from
H827L, H1486L, H827L/H1486L and H827F/H1486F are significantly
different from that of wild-type NBD1 (11.7 μM 8-N3ATP) or wild-type
NBD2 (32.4 μM 8-N3ATP). In contrast, the Kd values of NBD1 or NBD2 from
H827F or H1486F are not significantly different from that of wild-type NBD1
(11.7 μM 8-N3ATP) or wild-type NBD2 (32.4 μM 8-N3ATP).
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20 mM HEPES (pH 7.05), 137 mM NaCl, 5 mM KCl, 0.7 mM Na2HPO4,
6 mM dextrose and 125 mM CaCl2 [31]. Surviving individual colonies in
media containing 200 μM methotrexate were picked and amplified. Cells for
membrane vesicle preparation were grown in DMEM/F12 media containing
5% fetal bovine serum and 200 μM methotrexate in roller bottles (on a roller
machine from BELLCO). Spodoptera frugiperda 21 (Sf21) cells were cultured
in Grace's insect cell medium supplemented with heat-inactivated 5% fetal
bovine serum at 27 °C. Viral infection was performed according to Invitro-
gen's recommendation.
2.4. Recombinant viral DNA preparation and viral particle production
Generation of recombinant viral DNA was performed according to
Invitrogen's recommendation. pDual/N-half/C-half donor plasmid DNA was
transformed into DH10Bac competent cells harboring the parent Bacmid DNA
with a mini-attTn7 target site and the helper plasmid. Bacteria transformed with
the donor plasmid DNA were selected on LB plates containing 50 μg/ml
kanamycin, 7 μg/ml gentamicin and 10 μg/ml tetracycline. In addition, colonies
containing recombinant Bacmids were identified by disruption of the lacZα
gene (white colonies) on the LB plates containing 100 μg/ml X-gal and 40 μg/ml
IPTG. A single colony confirmed as having a white phenotype on the LB plate
with X-gal and IPTG was inoculated in medium containing 50 μg/ml
kanamycin, 7 μg/ml gentamicin and 10 μg/ml tetracycline. The purified
recombinant Bacmids were confirmed by polymerase chain reaction with MRP1
specific primers and then used to transfect Sf21 cells with CellFECTIN reagent.
After 3–4 days incubation at 27 °C, the supernatants containing viral particles
were collected and the cells were lysed with 2% SDS, separated on a 7%
polyacrylamide gel, electro-blotted to a nitrocellulose membrane and probed
with MRP1-specific monoclonal antibodies 42.4 and 897.2 [20].
2.5. Viral plaque assay and viral infection
Viral plaque assay was performed according to Invitrogen's recommenda-
tion. The expression levels of the dual-expressed N-halves and C-halves with
varying multiplicity of infection (MOI) were determined by Western blot. MOI
of 8 was used to infect Sf21 cells for membrane vesicle preparations.
2.6. Identification of MRP1 protein
Western blot was performed according to the method described previously [20].
42.4 monoclonal antibody was used to identify the NBD1-containing N-half
fragment of MRP1, whereas 897.2 monoclonal antibody was used to detect the
NBD2-containing C-half fragment [20,27]. The secondary antibody used was anti-
mouse Ig conjugatedwith horse radish peroxidase. Chemiluminescent film detection
was performed according to the manufacturer's recommendations (Pierce).
2.7. Membrane vesicle preparations
Membrane vesicles were prepared according to the procedure described
previously [20]. The membrane vesicle pellet was re-suspended in a solution
containing 10 mM Tris–HCl (pH 7.5), 250 mM sucrose and 1× protease inhibitors
(2 μg/ml aprotinine, 121 μg/ml benzamidine, 3.5 μg/ml E64, 1 μg/ml leupeptin and
50 μg/ml Pefabloc). After passage through a Liposofast™ vesicle extruder (Avestin,
Ottawa, Canada) they were divided into 200 μl aliquots and stored in −80 °C.
2.8. Membrane vesicle transport
ATP-dependent LTC4 transport was assayed by a rapid filtration technique
[32,33]. Briefly, 30 μl solution containing 3 μg of membrane proteins,
50 mM Tris–HCl (pH 7.5), 250 mM sucrose, 10 mM MgCl2, 200 nM LTC4
(17.54 nCi of 3H-labeled LTC4) and 4 mM ATP (4 mM AMP was used as
control) were mixed on ice and then incubated at 37 °C for 4 min. The
samples were brought back to ice, diluted with 1 ml of ice-cold 1× transport
buffer (50 mM Tris–HCl, pH 7.5, 250 mM sucrose and 10 mM MgCl2)
immediately and trapped on nitrocellulose membranes (0.2 μm) that had been
equilibrated with 1× transport buffer. The filter was then washed with 10 mlof ice-cold 1× transport buffer, air-dried and placed in a 10 ml of
biodegradable counting scintillant (Amersham Pharmacia Biotech). The
radioactivity bound to the nitrocellulose membrane was determined by liquid
scintillation counting (Beckman LS 6000SC).
2.9. Photoaffinity labeling of MRP1 protein
Vanadate (Vi) preparation and photoaffinity labeling of MRP1 protein were
performed according to procedures described previously [20]. Briefly,
photolabeling experiments were carried out in a 10 μl solution containing
10 μg membrane vesicles, 40 mM Tris–HCl (pH 7.5), 2 mM ouabain, 10 mM
MgCl2 and 0.1 mM EGTA. Concentration of
32P-labeled nucleotide, Vi,
incubation time and temperature are specifically indicated in Figs. 2 and 3. The
labeled proteins were separated by polyacrylamide gel (7%) electrophoresis and
electro-blotted to a nitrocellulose membrane.
2.10. Statistical analysis
The results in Tables 1 and 2 were presented as means±S.D. from three
(Table 1) or four (Table 2) independent experiments. The two-tailed P values
were calculated based on the unpaired t test from GraphPad Software Quick
Calcs. By conventional criteria, if P value is less than 0.05, the difference
between two samples is considered to be statistically significant.
3. Results
3.1. Substitution of H827 in H-loop of NBD1 with an amino
acid that prevents formation of the hydrogen-bond with the
γ-phosphate of the bound ATP has no effect on the
ATP-dependent LTC4 transport whereas corresponding
mutation in NBD2 almost abolishes the ATP-dependent LTC4
transport activity completely
Structural analyses of bacterial ABC transporter NBDs
revealed that the histidine residue in H-loop contributes to
Table 2
Ratio of [γ-32P]-8N3ATP/[α-
32P]-8N3ATP labeling at NBD1 or NBD2
Samples Ratio a at NBD1 Ratio at NBD2
N-half C-half
Wild-type Wild-type 2.12±0.26 b 0.70±0.14
H827L Wild-type 1.92±0.45 0.90±0.02
Wild-type H1486L 1.89±0.34 1.26±0.12
H827L H1486L 2.12±0.32 1.38±0.33
H827F Wild-type 2.17±0.15 0.93±0.02
Wild-type H1486F 2.15±0.10 1.42±0.14
H827F H1486F 1.98±0.20 1.42±0.19
a The ratio (n=4) of [γ-32P]-8-N3ATP/[α-
32P]-8-N3ATP labeling at NBD1 or
NBD2 was derived from Fig. 3. The amount of 32P-8-N3ATP incorporated into
the N-half (NBD1) or C-half (NBD2) fragment was measured by employing
Packard Instant Imager. The ratio of [γ-32P]-8-N3ATP/[α-
32P]-8-N3ATP
labeling at NBD1 or NBD2 was calculated by dividing the amount of [γ-32P]-
8-N3ATP labeling with that of [α-
32P]-8-N3ATP labeling.
b Statistical analysis indicated that the ratio values of NBD1 from all the
mutants are not significantly different from that of wild-type NBD1 (2.12). The
ratio values of NBD2 from H827L and H827F are also not significantly different
from that of wild-type NBD2. In contrast, the ratio values of NBD2 from
H1486L, H827L/H1486L, H1486F and H827F/H1486F are significantly
different from that of wild-type NBD2 (0.70).
Fig. 1. Substitution of H1486 in NBD2 with either a leucine or a phenylalanine
significantly decreases the ATP-dependent LTC4 transport activity. (A)
Substitution of histidine residue at H827 or H1486 with either a leucine (L)
or a phenylalanine (F). The highlighted letters indicate that the histidine residue
was substituted with either an L or an F at that position. The definition of H827L
means that the H827L-mutated N-half is co-expressed with wild-type C-half,
whereas H1486L means that the H1486L-mutated C-half is co-expressed with
wild-type N-half. (B) Expression of wild-type and variant mutants of human
MRP1 proteins in Sf21 insect cells. Membrane vesicles were prepared from
Sf21 cells infected with viral particles containing either wild-type or variant
mutants of human MRP1. The amounts of membrane vesicle protein loaded in
the gel are indicated on the top. Molecular weight markers are indicated on the
left. NH and CH on the right indicate the N-proximal half and the C-proximal
half of MRP1 proteins that were detected in western blot by employing the
monoclonal antibody 42.4 against NBD1 and 897.2 against NBD2. The
intensities of the N-half and C-half bands were determined by a scanning
densitometer. The mean ratios (n=3), considering the amount of wild type N-
half and C-half of MRP1 as 1, of the mutant proteins including N-half and C-half
in the membrane vesicles are listed at the bottom of the gel. (C) Relative rate of
ATP-dependent LTC4 transport activity. The assays were carried out in a 30 μl
solution containing 3 μg of membrane vesicles (the amount of MRP1 protein
determined in B was adjusted to a similar amount by adding varying amount of
membrane vesicles prepared from Sf21 cells infected with pDual expression
vector) and 4 mMAMP (used as a control) or 4 mMATP at 37 °C for 4 min. The
amount of LTC4 bound to the membrane vesicles in the presence of 4 mM AMP
was subtracted from the corresponding samples in the presence of 4 mM ATP.
The data are means±S.D. of four triplicate-determinations.
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bound ATP [28,34,35] and to ATP hydrolysis by interacting
with the putative catalytic base to form the “catalytic dyad”
[29]. Alignment of amino acid sequences in NBDs indicates
that majority of the ABC transporters conserves the histidine
residue in H-loop [28] downstream of the Walker B motif.
However, there are some exceptions, such as a Y in NBD1
of pDR5 [36], a Q in TAP1 [37], an N in NBD1 of YCF1
[38] and an S in NBD1 of CFTR [39], implying that these
residues in H-loop, including Y, Q, N or S, might have a
potential to form hydrogen-bonds with the γ-phosphate of
the bound ATP and the putative catalytic base to form the
“catalytic dyad”.
In order to test the functional role of these hydrogen-
bond formations between the histidine residue in H-loop
and the components mentioned above, this histidine residue
was substituted with a residue that could abolish the for-
mation of this hydrogen-bond, such as a leucine (L) residue
or a phenylalanine (F) residue (Fig. 1A). These mutants
made in N-half, including H827L or H827F in NBD1, or
in C-half, including H1486L or H1486F in NBD2 or H827L/
H1486L and H827F/H1486F in N-half and C-half, were
expressed simultaneously in Sf21 insect cells. The results
in Fig. 1B indicated that both N-half and C-half of MRP1
proteins were expressed simultaneously. Membrane vesicles
prepared from Sf21 cells infected with viral particles con-
taining variant mutants and pDual vector (used as a con-
trol) were used for ATP-dependent LTC4 transport assay
(Fig. 1C). Mutations at NBD1, including H827L and H827F,
did not have a significant effect on the ATP-dependent
LTC4 transport, whereas mutations at NBD2, including
H1486L, H1486F, H827L/H1486L and H827F/H1486F,
greatly decreased the ATP-dependent LTC4 transport activity
(Fig. 1C).
328 R. Yang, X. Chang / Biochimica et Biophysica Acta 1768 (2007) 324–3353.2. Substitution of the imidazole ring in histidine residue in
H-loop with a benzene ring in phenylalanine did not
significantly affect ATP binding, whereas substitution of this
histidine residue with a hydrophobic leucine significantly
decreased the affinity for 8-N3ATP
Since histidine residue in H-loop forms hydrogen-bond with
the γ-phosphate of the bound ATP and contributes to the ATP
binding, substitution of this histidine residue with an amino acid
that prevents formation of hydrogen-bond with the γ-phosphate
of the bound ATP should decrease the affinity for ATP at the
mutated site. In order to test this hypothesis, membrane vesicles
containing wild type or variant mutants were used to label with
[α-32P]-8-N3ATP on ice (Fig. 2). Since the labeling on ice
mainly reflects the equilibrium of the following forwarding and
reversing reactions:
½a-32P-8-N3ATPþ NBD⇌k1k1 ½a-
32P-8-N3ATPd NBD
where the velocity of forwarding reaction vf = k1{NBD}
{[α-32P]-8-N3ATP} and the velocity of reversing reaction
vr =k−1{[α-
32P]-8-N3ATP·NBD}. At the equilibrium, the velo-
city of forwarding reaction vf equals to the velocity of reversing
reaction vr, thus, k1{NBD}{[α-
32P]-8-N3ATP}=k−1{[α-
32P]-
8-N3ATP·NBD}, k−1/ k1 = {NBD}{[α-
32P]-8-N3ATP}/
{[α-32P]-8-N3ATP·NBD}.
The Kd value for each NBD, where Kd=k−1/k1, should
reflect the affinity for 8-N3ATP. Mutation of H827L increased
the Kd (8-N3ATP) value of the mutated NBD1 from 11.7 μM
(wild-type NBD1, Fig. 2A and Table 1) to 59.5 μM (Fig. 2B and
Table 1), implying that H827L mutation decreased the affinity
for 8-N3ATP at the mutated NBD1. Interestingly, this mutation
also increased the Kd (8-N3ATP) value of NBD2 (60.0 μM, Fig.
2B and Table 1) even though the amino acid sequences in
NBD2 were not changed, presumably the decreased ATP
binding at the H827L-mutated NBD1 altered the affinity for 8-
N3ATP at the un-mutated NBD2. Accordingly, mutation of
H1486L increased the Kd (8-N3ATP) value of NBD2 from
32.4 μM (wild-type NBD2, Fig. 2A and Table 1) to 58.7 μM
(Fig. 2C and Table 1) and the Kd (8-N3ATP) value of the un-
mutated NBD1 from 11.7 μM (wild-type NBD1) to 31 μM (Fig.
2C and Table 1). Thus, it is not surprising that the double mutant
H827L/H1486L increased both Kd (8-N3ATP) values for NBD1
and NBD2 (Fig. 2D and Table 1). However, substitution of this
histidine residue in H-loop with an aromatic F residue in either
NBD1 (H827F) or NBD2 (H1486F) did not significantly alter
the Kd (8-N3ATP) values at either NBD1 or NBD2 (Fig. 2E, F
and Table 1), suggesting that replacement of the five-member
imidazole ring with the six-member benzene ring did not
significantly alter the local conformation in ATP binding
pocket, especially the van der Waals interactions with the
residues in D-loop of counterpart NBDs [29], and hydrogen-
bond formation between the residue at 827 or 1486 and the γ-
phosphate of ATP bound at that site played a minor role for
ATP-binding. However, the double mutant H827F/H1486F did
significantly increase the Kd (8-N3ATP) values for the H827F-mutated NBD1 and H1486F-mutated NBD2 (Fig. 2G and Table
1), presumably the tertiary structure alterations caused by these
two mutations affect ATP binding at the mutated NBD1 and
NBD2.
3.3. Substitution of the H1486 in H-loop with either an L or an
F decreased the rate of ATP hydrolysis at the mutated NBD2
Although substitution of H1486 residue in H-loop with an
aromatic F residue did not significantly affect 8-N3ATP binding
(Fig. 2F and Table 1), this mutation did significantly decrease
the ATP-dependent LTC4 transport (Fig. 1C). Since histidine
residue in H-loop may contribute to ATP hydrolysis by
interacting with the putative catalytic base to form the “catalytic
dyad” [29], we speculated that even though ATP can efficiently
bind to the H1486F-mutated NBD2, but the bound ATP cannot
be efficiently hydrolyzed. In order to test this hypothesis, these
mutated MRP1 proteins in membrane vesicles were labeled
with either [α-32P]-8-N3ATP or [γ-
32P]-8-N3ATP in the pres-
ence of vanadate at 37 °C (Fig. 3). In that case, the vanadate-
trapped [α-32P]-8-N3ATP hydrolysis product [α-
32P]-8-N3ADP
can still label the NBD whereas the vanadate-trapped [γ-32P]-8-
N3ATP hydrolysis product 8-N3ADP cannot. Thus, a high ratio
of [γ-32P]-8-N3ATP/[α-
32P]-8-N3ATP labeling at either NBD1
or NBD2 should reflect that ATP bound at that specific NBD
was not efficiently hydrolyzed. The ratio (Table 2) of [γ-32P]-8-
N3ATP/[α-
32P]-8-N3ATP labeling at either NBD1 (NH) or
NBD2 (CH) was calculated based on the counts in each band
(Fig. 3). The ratio of 2.12 in wild-type NBD1 is much higher
than the ratio of 0.70 in wild-type NBD2 (Table 2), implying
that the ATP bound to the wild-type NBD1 was not efficiently
hydrolyzed whereas the ATP bound to the wild-type NBD2 was
efficiently hydrolyzed. The ratio of [γ-32P]-8-N3ATP/[α-
32P]-
8-N3ATP labeling at the NBD1, regardless of whether this NBD
is mutated or not, is ∼ 2 (Table 2), implying that mutation of
H827 to either L or F at NBD1 does not have a significant effect
on the 8-N3ATP hydrolysis at this site. In addition, H827L or
H827F mutation did not significantly affect the ratio of the un-
mutated NBD2 (Table 2), consistent with their high LTC4
transport activities (Fig. 1C). In contrast, however, the ratio of
[γ-32P]-8-N3ATP/[α-
32P]-8-N3ATP labeling at the mutated
NBD2, regardless of whether this H residue is mutated to an
L or an F, including H1486L, H827L/H1486L, H1486F and
H827F/H1486F, is significantly increased (Table 2), implying
that the 8-N3ATP bound to the mutated NBD2 is not efficiently
hydrolyzed, consistent with their low LTC4 transport activities
(Fig. 1C).
3.4. The non-efficient ATP hydrolysis at the H1486L- or
H1486F-mutated NBD2 is not caused by global
conformational alterations
Since the N-halves and C-halves were expressed in Sf21
cells at 27 °C, the results derived from western blot in Fig. 1B
cannot tell whether these N-halves and C-halves were globally
folded properly or not. Thus, although it was clear that 8-N3ATP
bound to the H1486L- or H1486F-mutated NBD2 was not
Fig. 2. The effects of H827L, H1486L, H827L/H1486L, H827F, H1486F or H827F/H1486F mutations on 8-N3ATP binding at NBD1 and NBD2. Membrane vesicles
were prepared from Sf21 cells infected with viral particles containing either wild-type or variant mutants of humanMRP1. Photolabeling experiments were carried out
in a 10 μl of solution containing 10 μg membrane vesicle proteins and varying concentration of [α-32P]-8-N3ATP on ice for 10 min. The reaction mixture was UV-
irradiated on ice for 2 min, subjected to SDS-PAGE (7%) and electroblotted to a nitrocellulose membrane. Panel A shows the autoradiogram of [α-32P]-8-
N3ATP labeled wild-type N-half+wild-type C-half and the plots of the amount of [α-
32P]-8-N3ATP incorporated into wild-type N-half (NBD1) co-expressed with
wild-type C-half (NBD2). Panels B, C, D, E, F and G show the results derived from H827L-mutated N-half+wild-type C-half, wild-type N-half+H1486L-mutated
C-half, H827L-mutated N-half+H1486L-mutated C-half, H827F-mutated N-half+wild-type C-half, wild-type N-half+H1486F-mutated C-half and H827F-mutated
N-half+H1486F-mutated C-half. Molecular weight markers are indicated on the left. NH and CH on the right of the gel indicate the [α-32P]-8-N3ATP labeled N-half
and C-half of MRP1 proteins which were confirmed by western blots by employing the NBD1-specific monoclonal antibody 42.4 [20] and NBD2-specific monoclonal
antibody 897.2 [20].
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Fig. 2 (continued).
Fig. 3. Substitution of H1486 with either a leucine (L) or a phenylalanine (F)
decreased the rate of ATP hydrolysis at the mutated NBD2. Membrane vesicles
were prepared from Sf21 cells infected with viral particles containing either
wild-type or variant mutants of human MRP1. Photolabeling experiments were
carried out in a 10 μl of solution containing 10 μg membrane vesicle proteins,
800 μM vanadate and 10 μM of either [α-32P]-8-N3ATP (α) or [γ-
32P]-8-N3ATP
(γ) at 37 °C for 2 min. The reaction mixture was brought back to ice, UV-
irradiated on ice for 2 min, subjected to SDS-PAGE (7%) and electroblotted to a
nitrocellulose membrane. Molecular weight markers are indicated on the left.
NH and CH on the right of the gel indicate the 32P-8-N3ATP labeled N-half and
C-half of MRP1 proteins.
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caused by mis-folding of the protein introduced by the mutation
or by preventing hydrogen-bond formation between the residue
at 1486 and the γ-phosphate of the bound ATP or the putative
catalytic base. Since complex-glycosylated form of membrane-
bound protein in mammalian cells was used as a criterion to
indicate that the membrane glycoprotein was globally folded
properly, the H827L, H1486L, H827L/H1486L, H827F,
H1486F and H827F/H1486F mutations were introduced into
full length of MRP1 cDNA in pNUT/MRP1/His [31] and
expressed in BHK cells at 37 °C. The results in Fig. 4A clearly
indicate that all of these mutants form complex-glycosylated
mature proteins at 37 °C, ruling out the former possibility.
However, the amount of H827L/H1486L or H827F/H1486F
double-mutated MRP1 is slightly less than that of wild-type
MRP1 (Fig. 4A), implying that these double mutants might
affect the stability of the protein in BHK cells. Regardless of
whether these mutants would affect the protein stability or not,
the in vitro functional analyses by using membrane vesicles
Fig. 4. Prevention of hydrogen bond formation of the residue at 1486 in NBD2
with the γ-phosphate of the bound ATP and the putative catalytic base in this site
significantly decreased the ATP-dependent LTC4 transport activity. (A)
Expression of wild-type and variant mutants (shown on top of the gel) of full
length human MRP1 proteins in BHK cells at 37 °C. Membrane vesicles were
prepared from BHK cells expressing either wild-type or variant mutants of
human MRP1. The amounts of membrane vesicle protein loaded are indicated
on the top of the gel. Molecular weight markers are indicated on the left. MRP1
on the right indicates the 190 kDa complex-glycosylated human MRP1 proteins
that were detected in western blot by employing the monoclonal antibody 42.4.
The intensities of the 190 kDa bands were determined by a scanning
densitometer. The mean ratios (n=3), considering the amount of wild type
MRP1 as 1, of the mutant proteins are listed at the bottom of the gel. (B) Relative
rate of ATP-dependent LTC4 transport activity. The assays were carried out in a
30 μl solution containing 3 μg of membrane vesicles (the amount of MRP1
protein determined in A was adjusted to a similar amount by adding varying
amount of membrane vesicles prepared from BHK cells transfected with human
CFTR cDNA and 4 mM AMP (used as a control) or 4 mM ATP at 37 °C for
4 min. The amount of LTC4 bound to the membrane vesicles in the presence of
4 mM AMP was subtracted from the corresponding samples in the presence of
4 mM ATP. The data are means±S.D. of four triplicate-determinations.
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mutations on the protein function. The ATP-dependent LTC4
transport activities (Fig. 4B) of these full-length mutants,
including H827L, H1486L, H827L/H1486L, H827F, H1486F
and H827F/H1486F, are consistent with the results derived from
N-half+C-half (Fig. 1C), reinforcing the conclusions made in
Figs. 1, 2 and 3.
3.5. Hydrogen-bond formation of the residue at 1486 with the
γ-phosphate of the bound ATP and other residues, such as
putative catalytic base E1455, plays a crucial role during the
ATP-dependent solute transport by MRP1
If hydrogen-bond formation between the residue at 1486 and
the γ-phosphate of the bound ATP and the putative catalytic
base plays such an important role during ATP hydrolysis at
NBD2, substitution of the H residue in H-loop with amino acid
residues, such as D, N, E, Q, Y or W, that may potentially form
hydrogen-bonds with these components might rescue the ATP-
dependent LTC4 transport activity. In order to test this
hypothesis, H827D, H1486D, H827D/H1486D, H827N,
H1486N, H827N/H1486N, H827E, H1486E, H827E/H1486E,H827Q, H1486Q, H827Q/H1486Q, H827Y, H1486Y, H827Y/
H1486Y, H827W, H1486W and H827W/H1486W mutations
(Fig. 5A) were introduced into full length of MRP1 cDNA in
pNUT/MRP1/His and expressed in BHK cells at 37 °C. The
results in Fig. 5B indicate that all these mutants form complex-
glycosylated mature MRP1 proteins in BHK cells at 37 °C.
Consistent with the H827L or H827F mutation in NBD1, all of
the NBD1 mutants, including H827D, H827N, H827E, H827Q,
H827Y and H827W, have transport activities similar to that of
wild-type MRP1 (Fig. 5C), implying that no matter whether or
not these NBD1 mutants form hydrogen-bonds with these
components, none of them has a significant effect on the ATP
hydrolysis at the un-mutated NBD2 and the ATP-dependent
solute transport. However, in contrast, mutations in NBD2 have
variant effects on the ATP-dependent solute transport (Fig. 5C).
For example, H1486Q had similar transport activity (112%) as
that of wild-type MRP1 (Fig. 5C), whereas H1486E dropped
this activity to ∼36% of the wild-type (Fig. 5C). H1486N had
∼60% of wild-type MRP1 transport activity, whereas H1486D
dropped this activity to ∼20%. Interestingly, although H1486F
dropped this transport activity to ∼15%, substitution of the
Fig. 5. Hydrogen-bond formation of the residue at 1486 with the γ-phosphate of
the bound ATP and the putative catalytic base in this site plays a crucial role in
ATP-dependent solute transport. (A) Substitution of the histidine residue at 827
or 1486 with variant amino acids, including D, N, E, Q, Y and W, that may
potentially form hydrogen-bond with the γ-phosphate of the bound ATP and
putative catalytic base in NBD2. The highlighted letters indicate that the H
residue at that position was substituted with D, N, E, Q, Yor W. (B) Expression
of wild-type and variant mutants of full length human MRP1 proteins in BHK
cells at 37 °C. Membrane vesicles were prepared from BHK cells transfected
with either wild-type or mutants and used to do western blot by employing the
NBD1-specific monoclonal antibody 42.4 [20]. The amounts of membrane
vesicle protein loaded in the gel are indicated on top of the gel. Molecular weight
markers are indicated on the left. MRP1 on the right indicates the 190 kDa
complex-glycosylated human MRP1 proteins. The intensities of the 190 kDa
bands were determined by a scanning densitometer. The mean ratios (n=3),
considering the amount of wild type MRP1 as 1, of the mutant proteins are listed
at the bottom of the gel. (C) Relative rate of ATP-dependent LTC4 transport
activity. The assays were carried in the same way as described in Fig. 4. The data
are means±S.D. of four triplicate-determinations.
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the benzene ring of F residue that might potentially form
hydrogen-bonds with the γ-phosphate of the bound ATP and the
putative catalytic base E1455, increased this transport activity
from 15% to 42% (Fig. 5C). In contrast, substitution of this H
residue in H-loop with another aromatic W residue (H1486W),
which might also form the hydrogen-bond between the nitrogenatom in the ring structure of tryptophan and the γ-phosphate of
the bound ATP and the putative catalytic base E1455, dropped
this transport activity to ∼21% (Fig. 5C). In addition, the
transport activities of the double mutants are either similar to or
less active than the corresponding NBD2 mutants (Fig. 5C),
implying that mutations at NBD2 play a dominant role for the
ATP-dependent solute transport.
4. Discussion
ATP binding to NBD1 of MRP1 induced conformational
changes of the protein and enhanced nucleotide binding at
NBD2 [22]. If the stereo-structure of a nucleotide is altered,
nucleotide binding to NBD1 may not induce the proper
conformational changes that enhance the nucleotide binding at
NBD2. For example, the angle of P–N–P in AMP–PNP is
slightly different from that of P–O–P in ATP, in other words, the
relative location of the γ-phosphate or the stereo-structure of
AMP–PNP is different from that of ATP. Although AMP–PNP
can bind to NBD1 of MRP1, this binding cannot enhance the
AMP–PNP binding or vanadate-dependent ADP trapping to
NBD2 [22,40], implying that precise stereo-interactions
between the residues in MRP1 and the bound nucleotide are
required to induce the proper conformational changes of the
protein. Nucleotide binding to NBD1 and NBD2 may be
sufficient to transport the bound substrate LTC4 from high
affinity site to low affinity site [30]. However, this translocation
also requires proper stereo-structure of a nucleotide. For
example, ATPγS binding to MRP1 can transport the bound
LTC4 from high to low affinity site whereas AMP–PNP cannot
[30]. Accordingly, this translocation also requires proper stereo-
structures of the NBDs of MRP1. For example, ATP binding to
wild-type MRP1 can transport the bound LTC4 from high to
low affinity site whereas ATP binding to the K684R- or the
D1454N-mutated MRP1 cannot [30].
H827L-, H827F-, H827D-, H827N-, H827E-, H827Q-,
H827Y- and H827W-mutated MRP1 form complex glycosy-
lated mature protein in BHK cells at 37 °C (Figs. 4A and 5B),
implying that these mutations in NBD1 did not significantly
alter the protein conformation. In addition, BHK cells
expressing H827L-mutated MRP1 exerted similar resistance
to daunomycin as wild-type (data not shown), implying that
H827L-mutated MRP1 was properly routed to the plasma
membrane. These NBD1 mutants, regardless of whether they
were expressed in the form of N-half+C-half in Sf21 cells or
full length in BHK cells, did not significantly affect the ATP-
dependent LTC4 transport activity (Figs. 1C, 4B and 5C),
implying that these mutations in NBD1 did not have significant
effects on ATP hydrolysis at the un-mutated NBD2. Since some
of these mutations, such as H827L or H827F, definitely prevent
formation of the hydrogen-bonds of the residue at 827 with the
γ-phosphate of the bound ATP [28,34,41–43], it is reasonable
to predict that these mutations would decrease the affinity for
ATP at the mutated NBD1. Indeed, H827L mutation signifi-
cantly increased the Kd (8-N3ATP) values of the mutated NBD1
(Fig. 2 and Table 1) and the un-mutated NBD2 (Fig. 2 and Table
1), implying that hydrogen-bond formation between the residue
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to ATP binding. However, in contrast, H827F mutation did not
significantly affect the Kd (8-N3ATP) values of the mutated
NBD1 and the un-mutated NBD2 (Fig. 2 and Table 1). These
results were interpreted as that: (1) proper conformation of the
ATP binding pocket may play a major role for ATP binding,
whereas hydrogen-bond formation between the residue at 827
and the γ-phosphate of the bound ATP may play a minor role
for ATP binding; (2) H827L mutation may induce micro-
conformational changes in ATP binding pocket that decrease
affinity for ATP at the mutated NBD1 and then subsequently at
the un-mutated NBD2; (3) substitution of the five-member
imidazole ring in histidine with six-member benzene ring in
phenylalanine definitely prevented formation of hydrogen
bonds with the γ-phosphate of the bound ATP and the putative
catalytic base D793, but retained van der Waals interactions
with the residues in D-loop of NBD2 [29]. Interestingly,
structural analysis of recombinant human MRP1-NBD1
revealed that the “catalytic dyad” formed between D793 and
H827 pointed away from the γ-phosphate of the bound ATP in
this site [45], implying that H827 may not form hydrogen-bond
with the γ-phosphate of the bound ATP. This orientation also
explained why NBD1 of human MRP1 protein has low ATPase
activity [19,20]. Since mutations of H827L and H827F also
prevent the formation of this “catalytic dyad” between D793
and L827 or F827, fully functional H827L- or H827F-mutated
MRP1 suggests that formation of the “catalytic dyad” between
D793 and H827 is not important for MRP1 function. In
addition, since none of these NBD1 mutants significantly
affects the ATP-dependent LTC4 transport (Figs. 1C, 4B and
5C), it means that ATP binding to these mutated NBD1s still
stimulates nucleotide binding at the un-mutated NBD2 [22].
In contrast, mutations in NBD2, such as H1486L, H1486F,
H1486D, H1486N, H1486E, H1486Q, H1486Y and H1486W,
have variant effects on the ATP-dependent LTC4 transport
(Figs. 1C, 4B and 5C)). Substitution of the H1486 in H-loop
with residues that would not form hydrogen-bond with the γ-
phosphate of the bound ATP in NBD2, including H1486L-,
H1486F-, H827L/H1486L- or H827F/H1486F-mutated MRP1,
severely impaired the ATP-dependent LTC4 transport, pre-
sumably because the bound ATP at the mutated NBD2 (Fig. 2C,
D, F and G) were not efficiently hydrolyzed (Fig. 3 and Table
2). These results reinforce our conclusion that ATP hydrolysis at
NBD2 plays a crucial role for ATP-dependent solute transport
[21]. However, why H1486F mutation did not significantly
affect 8-N3ATP binding (Fig. 2F and Table 1) but severely
impaired the ATP hydrolysis at the mutated NBD2 (Fig. 3 and
Table 2) was not well understood. These results were interpreted
as that replacement of the imidazole ring in histidine with
benzene ring in phenylalanine did not lose the ability to interact
with the residues in D-loop of NBD1 via van der Waals
interactions [29] and kept the NBD1·ATP·ATP·NBD2 sand-
wich structure intact, but lost ability to form hydrogen bond
with the γ-phosphate of the bound ATP [28,34,41–43] and to
form “catalytic dyad” with the putative catalytic base E1455
[29,45]. The only difference between H1486F and H1486Y is
that H1486Y has an extra hydroxyl group on the benzene ring.H1486F mutation almost abolished the ATP-dependent LTC4
transport activity completely (Figs. 1C and 4B), whereas
H1486Y mutation retained ∼41% of wild-type LTC4 transport
activity (Fig. 5C), presumably the hydroxyl group on the
benzene ring of tyrosine provides a possibility to form
hydrogen-bond with the γ-phosphate of the bound ATP. This
means that hydrogen-bond formation between the residue at
1486 and the γ-phosphate of the bound ATP may play a very
important role during ATP hydrolysis. The above results could
also be interpreted as that the hydroxyl group on the benzene
ring of tyrosine provides a possibility to form a “catalytic dyad”
with the putative catalytic base E1455. This means that the
“catalytic dyad” formation may also play a very important role
during ATP hydrolysis.
Regardless of which mechanism plays an important role,
substitution of this histidine residue with an amino acid that
would potentially prevent formation the hydrogen bond between
the residue in H-loop and the γ-phosphate of the bound ATP or
the putative catalytic base should severely impair the ATP
hydrolysis at the mutated site. Indeed, several substitutions of
this histidine residue in H-loop with amino acids that prevented
formation of hydrogen bonds severely impaired the ATP
hydrolysis and ATP-dependent solute transport. For example,
substitution of H211 in HisP with an arginine residue did not
significantly affect ATP binding [46], but the H211R mutant
neither supported ATP hydrolysis nor histidine translocation
[46,47]; replacement of H662 in HlyB with an alanine residue
completely abolished the ATPase activity [44]; substitution of
H192 in MalK with an arginine residue abolished ATP
hydrolysis [48] and ATP-dependent maltose uptake [48,49].
In contrast, substitution of the histidine residue in H-loop
with an amino acid that might potentially form the hydrogen-
bonds should support the ATP hydrolysis and ATP-dependent
solute transport. Indeed, H1486Q-mutated MRP1 is fully active
(Fig. 5C), implying that the hydrogen-bond formations between
Q1486 and the γ-phosphate of the bound ATP or the putative
catalytic base E1455 are as strong as in wild-type. However,
H1486E exerts ∼36% of wild-type MRP1 transport activity
(Fig. 5C), presumably the carboxyl group of E1486 cannot form
strong hydrogen-bonds with the γ-phosphate of the bound ATP
and the putative catalytic base E1455 in NBD2. Accordingly,
although H1486N has the same side group as the H1486Q
mutation, except that the length of the side chain in H1486N is
one carbon (or 1.541 Å) shorter than in H1486Q, the transport
activity of H1486N dropped from ∼112% (H1486Q) to ∼60%
(Fig. 5C), implying that the distance between two groups
forming hydrogen-bond also plays an important role. The
transport activity of H1486D dropped from ∼36% (H1486E) to
∼20% (Fig. 5C), consistent with the above conclusion. In
addition, substitution of H587 or H1232 in P-gp with a Q residue
did not significantly affect the ATPase activity of the protein,
whereas substitution of H587 or H1232 with an alanine residue
completely abolished the ATPase activity (Suresh Ambudkar,
personal communication), reinforced our above hypothesis.
Interestingly, the ATP-dependent LTC4 transport activities
of the double mutants, including H827L/H1486L, H827F/
H1486F, H827L/H1486L, H827F/H1486F, H827L/H1486L,
334 R. Yang, X. Chang / Biochimica et Biophysica Acta 1768 (2007) 324–335H827F/H1486F, H827L/H1486L and H827F/H1486F, are
either similar to or lower than their corresponding mutations
in NBD2 (Figs. 4B and 5C), supporting our conclusion that ATP
hydrolysis at NBD2 plays a crucial role for ATP-dependent
solute transport by MRP1 [21].
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